Oriol Mitjà | |
|---|---|
 | |
| Born | 1980 (age 44–45) |
| Alma mater | |
| Occupation | Medical doctor,scientist |
| Employer |
|
| Awards |
|
Oriol Mitjà i Villar (born 1980)[1] is aCatalan-bornSpanishresearcher and consultant physician ininternal medicine and infectious diseases with expertise inpoverty-relatedtropical diseases. He has conducted research at the Lihir Medical Centre inPapua New Guinea since 2010 on new diagnostic and therapeutic tools to eradicateyaws.[2] He was awarded the Princess of Girona Award in the scientific research category. Currently at the Germans Trias i Pujol Research Institute, Autonomous University of Barcelona, Mitjà is conducting research on SARS-CoV-2 coronavirus disease (COVID-19) and strategies to control the infection at a community level.[3][4]
Oriol Mitjà graduated inmedicine from theUniversity of Barcelona in 2004, after completing a residency ininfectious diseases[5] and a diploma inHygiene and Tropical Medicine at theLondon School of Hygiene & Tropical Medicine.[6] In 2012, he finished his Ph.D. in Medicine in Barcelona; histhesis was entitled "Strategies for the control of the yaws and other neglected tropical diseases of the South Pacific islands" and was based on his on-site research at theLihir medical center inPapua New Guinea.[7]
After finishing his activity as aresident doctor, Mitjà focused on the development of diagnostic and therapeutic solutions to control and eradicate skin neglected tropical diseases, particularly yaws - which is a chronic and debilitating bacterial infection that affects the skin and bones.
Since 2010, he collaborated with theBarcelona Institute of Global Health. He conducted a randomized trial that was published in 'The Lancet'[8] that revealed that a single-dose oral azithromycin is effective to cure yaws and is easier and safer to administer as compared to the standard treatment with injectable penicillin. Accordingly, the World Health Organization (WHO) changed the treatment policies to recommend the use of azithromycin as the first-line treatment for yaws.
The previous yaws eradication campaign was launched in 1952 with estimated cases totaled 50 million worldwide. Twelve years later, prevalence had plunged by 95%. Governments and funding agencies soon lost interest and infection rates began climbing back up in the 1970s. The present WHO eradication strategy for yaws is mass treatment with single-dose oral azithromycin, followed by resurveys to find residual cases. Mitjà has demonstrated that the new strategy is effective in eliminating yaws from endemic countries and if implemented everywhere could result in yaws eradication, which was published in theNew England Journal of Medicine.
In 2018, Oriol Mitjà transferred his research lines to the Germans Trias i Pujol Research Institute. From 2020 to 2023, he worked to transfer his knowledge on epidemiology into clinical solutions for theSARS-CoV-2 pandemic. Mitjà conducted research to advance knowledge in the field of therapeutics, where he aimed at repurposing existing therapies to reduce the risk of infection with the SARS-CoV-2 coronavirus. In particular, he led a clinical trial that showed that post-exposure prophylaxis with hydroxychloroquine was not effective to preventSARS-CoV-2, The results of this research were published in theNew England Journal of Medicine.[9] Additionally, Mitjà lead studies that showed that treatment based on and immunoglobulin anti-SARS-CoV-2, and of a treatment based on the transfusion of convalescent plasma, did not provide protection to people exposed to the virus.
Mitjà has repeatedly spoken in favor of intensifying the SARS-CoV-2 prevention and containment strategy and requested full lockdown in Spain during the month of March 2020.[4] He has coordinated the drafting of an expert report commissioned by the Government of Catalonia that was delivered on April 21, 2020.
Since 2022, he has led studies on monkeypox (mpox), establishing an international network to describe its clinical manifestations and vaccine protection. He is currently working on the development of new treatments for syphilis in adults, congenital syphilis, and neurosyphilis, including clinical trials with linezolid as an alternative to penicillin.[10]
In 2012, Mitjà was awarded theSwissFoundation Anne-Maurer Cecchini prize as a result of the publication of the aforementioned study re yaws inThe Lancet
In 2013, he was awarded thePrince of Girona Foundation[11] forScientific Research for his "exemplary dedication in the field of endemic infectious diseases in developing countries and the great international impact of his work aimed at eradicating yaws disease of the planet".
In 2015, a documentary about his research project called "Where the Roads End" was produced by Noemí Cuní/David Fonseca.
In 2016, he received theCatalan of the Year Award and in 2017 received peace awards from theAssociation for United Nations in Spain[12] and theInternational Award Alfonso Comín,[13] in recognition of his work in favour of improving the living conditions of the people affected by the yaws.
In 2019, he was awarded a European Research Council Starting Grant to support research that aims to repurpose drugs to treat syphilis.[14] In 2024, he was awarded a European Research Couoncil Consolidator Grant to support research on neurosyphilis and syphilis in pregnancy,[15]
| International | |
|---|---|
| National | |
| Academics | |
